NM404 as an Imaging Agent in Patients With NSCLC
This study seeks to determine imaging characteristics of radiolabelled 131-I-NM404 in ten patients with cancer, including calculations of PKs, radiation dosimetry, biodistribution, and optimal imaging times (part 1 - complete). In addition, specific tumor accumulation and metabolic fate of 131-I-NM404 will be determined in NSCLC tumors collected in 5 patients (part 2 - complete). Lastly, the study will collect preliminary data on imaging NSCLC tumors in up to 12 patients with evaluable disease (part 3 - ongoing).
Checked against the public recordLast updated May 22, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- University of Wisconsin, Madison
- Interventions being studied
- Drug: I124-NM404
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Part 3 * Histologically or cytologically documented NSCLC with measurable of disease * Disease is evaluable by CT scan * At least 18 years old. Women cannot be pregnant or breastfeeding * Karnofsky score \>/= to 60 * Adequate renal/hepatic function * Adequate blood cell count levels Exclusion Criteria: * Concomitant infection * Other active cancers
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Wisconsin Carbone Comprehensive Cancer CenterMadison, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 22, 2019. Always confirm current availability with the study team.